Drug Discovery
Biotechnology
Fierce Biotech
Computational Chemistry
Longevity Tech
TechBio vs Biotech
Retrieved sources
[1] Isomorphic Labs — https://www.isomorphiclabs.com/
yaml
founded_year: "2021"
funding: Total funding USD 2,701,700,000; notable rounds include Seed (2022-04-01) USD 1.7M, Seed (2023-09-01), Corporate round (2021-11-01), Venture (2025-03-01) USD 600.0M, Series B (2026-05-01) USD 2.1B
name: Isomorphic Labs
headquarters:
address: London, GB
city: London
country: United Kingdom
workforce:
total: 447
financials:
revenueAnnual: 155500000
fundingTotal: 2701700000
fundingLatestRound:
name: Series b
date: 2026-05-01
amount: 2100000000 Value Proposition & Features
Isomorphic Labs is a London-based biotechnology research company developing AI systems for drug design and discovery, with the goal of accelerating medicine development and improving human health.
[1]
It describes its model as developing AI models, generating biological data, discovering new biology, and advancing potential medicines toward clinical testing.
[2]
Priority features:
- Unified AI drug-design engine: IsoDDE is intended to integrate molecular-structure prediction, biological-activity modeling, and candidate design in one system. [3]
- Protein–ligand prediction: Isomorphic reports improved prediction of protein and small-molecule binding structures compared with AlphaFold 3. [4]
- Antibody–antigen modeling: The company reports higher antibody–antigen structure-prediction accuracy than AlphaFold 3. [4]
- Binding-affinity estimation: IsoDDE estimates how strongly drug candidates bind biological targets without requiring experimental crystal structures. [4]
- Internal drug development: Isomorphic plans to use its models both with pharmaceutical partners and for medicines developed in-house. [6]
- Therapeutic-program development: Its stated objective is to move AI-designed candidates toward clinical trials. [7]
Product Roadmap / Announcements
As of October 8, 2026,
- October 7, 2026: Isomorphic Labs joined the Virtual Biology Initiative , a Biohub-convened effort involving funding, data, computation, and biological-measurement technologies to generate AI-ready biological data. [5]
- September 29, 2026: The company published an account of its integrated approach to medicine development, spanning AI-model development, data generation, biological discovery, and clinical translation. [2]
- End of 2026: The company is reported to be targeting initiation of its first clinical trials by the end of 2026. [7]
Recent Developments
Within the past 90 days, Isomorphic Labs joined the Virtual Biology Initiative and described a strategy to move from AI models and biological data through drug discovery and clinical development.
[2]
[5]
The company is also reported to be in early discussions about a potential financing at a valuation of at least $40 billion, although the financing had not closed and terms could change.
[6]
History and Origin Story
Isomorphic Labs was founded in 2021 as a spinout from Alphabet’s Google DeepMind, with the mission of applying DeepMind’s AlphaFold -related advances to drug discovery.
[6]
Its key inflection points include a reported $600 million financing in 2025, the development and publication of IsoDDE results in February 2026, and a $2.1 billion Series B in May 2026.
[8]
[9]
Fundraising History
| Round | Date | Amount | Lead investor |
| Corporate round | November 2021 | Undisclosed | Alphabet |
| Seed | April 2022 | $1.7M | Not disclosed |
| Seed | September 2023 | Undisclosed | Not disclosed |
| Venture | March 2025 | $600M | Not disclosed |
| Series B | May 2026 | $2.1B | Thrive Capital |
| Total | — | $2.7017B reported | — |
Sources for Table:
[9]
The retrieved company metadata reports total funding of approximately $2.7017 billion.
[1]
Notable Team Members
Demis Hassabis is associated with Isomorphic Labs through his leadership of Google DeepMind and the company’s origin as a DeepMind spinout.
[6]
The retrieved results do not provide a sufficiently authoritative, current leadership roster for additional named executives.
Market Sizing
Category, Market Size, and Category Growth
Isomorphic Labs operates in AI-enabled drug discovery , at the intersection of biotechnology, computational biology, and pharmaceutical research. Its commercial opportunity is tied to applying AI to reduce the time and cost of drug discovery and development.
[10]
Isomorphic Labs appears to operate through research collaborations, proprietary internal development, and pharmaceutical partnerships rather than a publicly documented self-serve software-pricing model.
[6]
Revenue Trajectory Estimates
The retrieved company metadata reports annual revenue of $155.5 million, but it does not explain whether this figure represents recognized revenue, partnership payments, licensing income, or another estimate.
[1]
Competitive Landscape
Who it's for, who it's not for
Isomorphic Labs is aimed at pharmaceutical companies, biotechnology researchers, and internal drug-development programs that need computational support for target biology, molecular design, candidate selection, and therapeutic development. Its announced collaborations with Eli Lilly and Novartis indicate a focus on large-scale pharmaceutical research partnerships.
[6]
It is not positioned in the retrieved sources as a general-purpose AI tool, a consumer health application, or a publicly accessible drug-design SaaS product; its models are described as internal and its work as partnership-based or in-house.
[11]
Viable Alternatives
- Insitro : AI-native drug-discovery and development company cited among Isomorphic Labs’ private competitors. [7]
- Enveda Biosciences : Computational and AI-oriented drug-discovery company listed as a competitor. [7]
Competitor Table
| Competitor | Description |
| Insitro | AI-native drug-discovery and development company cited as a private competitor. |
| Enveda Biosciences | Enveda Biosciences Biotechnology company using computational methods in drug discovery. |
| Anew Labs | Anew Labs Private company identified among Isomorphic Labs’ AI-drug-discovery competitors. |
| OpenAI | General AI company reported to have released a model for life-sciences research. |
| Eli Lilly | Eli Lilly Pharmaceutical company that is both an announced Isomorphic Labs partner and a large-scale drug-development alternative. |
Sources
[3] startupfortune.com · isomorphic-labs-seeks-fundingIsomorphic Labs seeks funding at a valuation of at least $40 ...
Sources (retrieved)
[1] Exa.ai API response for data on Isomorphic Labs